10.5 Cancer-Associated Thrombosis & Anticoagulation
Key Takeaways
- Venous thromboembolism is the second-leading cause of death in patients with cancer and occurs at roughly four to seven times the rate of the general population.
- The Khorana score stratifies chemotherapy-associated venous thromboembolism risk using tumor site, prechemotherapy platelet count, hemoglobin or growth factor use, leukocyte count, and body mass index, with a score of 2 or higher marking intermediate-to-high risk.
- Direct oral anticoagulants such as apixaban, rivaroxaban, and edoxaban are guideline-endorsed for cancer-associated thrombosis but carry increased major bleeding risk in luminal gastrointestinal and genitourinary malignancies, where low-molecular-weight heparin is preferred.
- Anticoagulation is generally continued for at least 6 months and for as long as the cancer is active or treatment continues.
- For platelet counts between 25,000 and 50,000/µL, dose-reduced anticoagulation with platelet transfusion support is used, and full-dose anticoagulation is generally held below 25,000/µL.
10.5 Cancer-Associated Thrombosis & Anticoagulation
Blueprint focus: ONCC Domain II.L and II.N — pharmacologic management of a treatment- and disease-related complication, and the interrelationship between the malignancy, its treatment, and a comorbid condition. Venous thromboembolism is common, lethal, and heavily protocolized, which makes it reliable exam material.
Scale of the Problem
Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer, after the cancer itself. Patients with malignancy have roughly four to seven times the VTE rate of the general population, and a VTE diagnosis independently predicts worse survival. Recurrence on anticoagulation is also far more common than in patients without cancer.
Virchow's triad in malignancy:
- Hypercoagulability — tumor cells express tissue factor and cancer procoagulant, release procoagulant microparticles, and generate inflammatory cytokines. Adenocarcinomas, particularly mucin-producing tumors, are the strongest drivers.
- Stasis — immobility from fatigue, hospitalization, surgery, and direct vascular compression by tumor or bulky adenopathy.
- Endothelial injury — central venous catheters, surgery, and endothelial-toxic drugs.
Highest-risk tumor types: pancreas, stomach, brain (particularly glioblastoma), lung, ovary, kidney, and hematologic malignancies including multiple myeloma treated with immunomodulatory agents.
Treatment-related contributors: cisplatin, immunomodulatory drugs (lenalidomide, thalidomide, pomalidomide) especially combined with dexamethasone, anti-angiogenic agents such as bevacizumab, tamoxifen, erythropoiesis-stimulating agents, high-dose corticosteroids, central venous catheters, and major abdominal or pelvic surgery.
Risk Assessment: The Khorana Score
| Variable | Points |
|---|---|
| Very high-risk tumor site — stomach, pancreas | 2 |
| High-risk tumor site — lung, lymphoma, gynecologic, bladder, testicular | 1 |
| Prechemotherapy platelet count ≥ 350,000/µL | 1 |
| Hemoglobin < 10 g/dL or use of an erythropoiesis-stimulating agent | 1 |
| Prechemotherapy leukocyte count > 11,000/µL | 1 |
| Body mass index ≥ 35 kg/m² | 1 |
Interpretation: 0 = low risk; 1 to 2 = intermediate; 3 or more = high risk. ASCO recommends considering thromboprophylaxis for ambulatory patients with a Khorana score of 2 or higher starting chemotherapy, after discussing bleeding risk.
Prophylaxis
| Setting | Recommendation |
|---|---|
| Hospitalized medical patients with active cancer | Pharmacologic prophylaxis unless actively bleeding or at high bleeding risk |
| Major cancer surgery | Pharmacologic prophylaxis started preoperatively or early postoperatively; extended prophylaxis for 4 weeks after major open abdominal or pelvic surgery |
| Ambulatory patients on chemotherapy | Not routine; consider apixaban, rivaroxaban, or low-molecular-weight heparin when the Khorana score is 2 or higher and bleeding risk is acceptable |
| Multiple myeloma on an immunomodulatory drug plus dexamethasone | Prophylaxis is required — aspirin for low-risk patients, low-molecular-weight heparin or a direct oral anticoagulant for higher-risk patients |
| Central venous catheters | Routine prophylaxis is not recommended |
| Primary brain tumors | Prophylaxis is used; a brain tumor is not by itself an absolute contraindication, although intracranial hemorrhage risk must be weighed |
Treatment of Established Cancer-Associated Thrombosis
Agent selection
| Agent class | Position | Cautions |
|---|---|---|
| Low-molecular-weight heparin (enoxaparin, dalteparin) | Long-standing standard; preferred with luminal gastrointestinal or genitourinary tumors, significant drug interactions, impaired absorption, vomiting, or severe thrombocytopenia | Renal dose adjustment; injection burden |
| Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban) | Guideline-endorsed and non-inferior for recurrence; oral convenience improves adherence | Increased major gastrointestinal and genitourinary bleeding, especially with intact luminal tumors; avoid with strong CYP3A4 and P-glycoprotein interactions; avoid in severe renal impairment |
| Unfractionated heparin | Used when rapid reversibility is needed, or with severe renal failure | Requires monitoring; heparin-induced thrombocytopenia risk |
| Warfarin | Inferior in cancer; erratic control from nutrition, vomiting, drug interactions, and hepatic metastases | Reserve for when the alternatives are contraindicated |
Duration
Anticoagulate for at least 6 months, and continue as long as the cancer is active, metastatic, or being treated. Reassess at intervals rather than stopping automatically at 6 months.
Recurrence on anticoagulation
Recurrent VTE while anticoagulated is common. Confirm adherence and absorption first, then escalate — typically by increasing the low-molecular-weight heparin dose by 20% to 25%, or converting a direct oral anticoagulant to low-molecular-weight heparin. Inferior vena cava filters are not first-line; they are reserved for absolute contraindications to anticoagulation, and should be retrieved once anticoagulation becomes possible.
Special Situations
Catheter-related thrombosis. Anticoagulate therapeutically. The catheter may stay in place if it is functional, correctly positioned, non-infected, and still needed. Remove it if it is non-functional, malpositioned, infected, or if symptoms persist despite anticoagulation — and when removal is necessary, give several days of anticoagulation first where feasible.
Thrombocytopenia. This is the most frequently tested nuance.
| Platelet count | Approach |
|---|---|
| > 50,000/µL | Full-dose anticoagulation |
| 25,000 to 50,000/µL | Dose-reduced anticoagulation, with platelet transfusion support to maintain the count above 40,000 to 50,000/µL during the acute period |
| < 25,000/µL | Generally hold full-dose anticoagulation; consider a retrievable IVC filter if the thrombus is recent and life-threatening |
Incidental pulmonary embolism discovered on a staging scan is treated the same as a symptomatic event, because outcomes are comparable.
Brain metastases are not an absolute contraindication; melanoma, renal cell carcinoma, and choriocarcinoma metastases carry the highest hemorrhage risk and warrant the most caution.
Neuraxial procedures — lumbar puncture, intrathecal chemotherapy, epidural placement — require agent-specific hold intervals to avoid spinal hematoma. Coordinate timing explicitly rather than assuming.
Patient Education
- Teach the symptoms of deep vein thrombosis (unilateral limb swelling, pain, warmth, erythema) and of pulmonary embolism (sudden dyspnea, pleuritic chest pain, hemoptysis, syncope, tachycardia) as call-immediately events.
- Teach injection technique, site rotation, and safe sharps disposal for low-molecular-weight heparin.
- Review bleeding precautions: soft toothbrush, electric razor, fall prevention, and avoidance of NSAIDs unless specifically approved.
- Emphasize that anticoagulation must not be self-discontinued because of minor bruising, and that any planned procedure requires advance coordination.
- Encourage mobility and hydration, and address the cost and injection burden that commonly drive silent non-adherence.
A 64-year-old man with metastatic gastric adenocarcinoma is diagnosed with an acute proximal deep vein thrombosis. His platelet count is 180,000/µL and creatinine clearance is 70 mL/min. Which anticoagulation strategy is most appropriate?
A patient receiving chemotherapy for pancreatic cancer has a prechemotherapy platelet count of 380,000/µL, hemoglobin of 9.6 g/dL, leukocyte count of 12,500/µL, and a body mass index of 27 kg/m². What is her Khorana score and what does it imply?
A patient on therapeutic enoxaparin for a pulmonary embolism develops chemotherapy-induced thrombocytopenia with a platelet count of 38,000/µL. What is the most appropriate management?